7 results on '"SKOV MADSEN, JONNA"'
Search Results
2. Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis.
- Author
-
Olesen, Mads Nikolaj, Wuolikainen, Anna, Nilsson, Anna Christine, Wirenfeldt, Martin, Forsberg, Karin, Skov Madsen, Jonna, Thue Lillevang, Soeren, Brandslund, Ivan, Munch Andersen, Peter, and Asgari, Nasrin
- Published
- 2020
- Full Text
- View/download PDF
3. Predicting brain metastases of breast cancer based on serum S100B and serum HER2.
- Author
-
BECHMANN, TROELS, SKOV MADSEN, JONNA, BRANDSLUND, IVAN, DALSGAARD LUND, ERIK, ORMSTRUP, TINA, JAKOBSEN, ERIK HUGGER, BAK JYLLING, ANNE MARIE, STEFFENSEN, KARINADAHL, and JAKOBSEN, ANDERS
- Subjects
- *
BREAST cancer research , *BRAIN metastasis , *EPIDERMAL growth factor receptors , *BLOOD proteins , *MAGNETIC resonance imaging of cancer , *COMPUTED tomography - Abstract
Brain metastases are a major cause of morbidity and mortality in breast cancer. The aim of the current study was to evaluate the prediction of brain metastases based on serum S100B and human epidermal growth factor receptor 2 (HER2). A total of 107 breast cancer patients were included in the current study from two prospective cohort studies with either elevated serum HER2 levels >15 ng/ml or brain metastases verified by magnetic resonance imaging (MRI) or computer tomography (CT). Following the exclusion of six patients, the remaining 101 patients were divided into two groups: Group 0 (n=55), patients with normal MRI results; and group 1 (n=46), patients with brain metastases. The levels of serum S100B and HER2 in the two groups were analyzed prior to MRI or CT of the brain, and no significant differences were identified in the serum HER2 (P=0.060) or S100B levels (P=0.623) between the groups. The univariate analysis of prognostic factors for brain metastases showed a significant correlation with systemic disease (P<0.001), axillary lymph node metastases (P=0.001) and serum HER2 >30 ng/ml (P=0.002). Only systemic disease (P<0.001) remained statistically significant in the multivariate analysis. In conclusion, serum levels of S100B and HER2 did not predict the risk of brain metastases. In the multivariate analysis, brain metastases were only found to correlate with systemic disease. However, in the univariate analysis, serum HER2 levels >30 ng/ml were identified to correlate with increased risk of brain metastases, which calls for further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
4. Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer.
- Author
-
Rabing Brix Petersen, Eva, Sørensen, Patricia Diana, Hugger Jakobsen, Erik, Skov Madsen, Jonna, and Brandslund, Ivan
- Subjects
TRASTUZUMAB ,BREAST cancer treatment ,HER2 gene ,DISEASE progression ,THERAPEUTICS - Abstract
Background: Serum HER2 (S-HER2) was approved in 2003 by the US Food and Drug Administration (FDA) for monitoring trastuzumab treatment in tissue HER2 positive breast cancer patients. Information of the value of S-HER2 is scarce. We hypothesised that S-HER2 would reflect the clinical effect of trastuzumab. Methods: We followed 48 patients eligible for trastuzumab treatment for up to 6 years or until death. S-HER2 was measured on an ADVIA Centaur System and S-Trastuzumab was measured by an in-house developed fluorescent enzyme immunoassay system on the ImmunoCap 100. Results: A decrease in S-HER2 of ≥ 20% was correlated to no progression in the disease in 20 out of 21 clinical courses (p<0.0001). An increase in S-HER2 of ≥ 20% was correlated to progression in the disease in 40 out of 44 clinical courses (p<0.0001). Patients with no recurrence after trastuzumab treatment (n=18) had a median S-HER2 concentration of 10.5 μg/L, whereas patients alive with recurrence (n=13) had a median S-HER2 of 20.1 μg/L (p=0.002). Patients who died prompted by recurrence (n=17) had a median S-HER2 of 232.4 μg/L at latest measurement before death (p=<0.0001) compared to patients without recurrence. In two patients with S-HER2 values above 1000 μg/L the concentrations of S-trastuzumab were measured below the target trough concentration in serum of 10 mg/L. Conclusions: Decreasing values of S-HER2 predicts response to treatment whereas increasing levels predict resistance. S-HER2 above 1000 μg/L warns that standard doses of trastuzumab may be insufficient as reflected by low concentrations of S-trastuzumab. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
5. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
- Author
-
Pedersen, Ann Christina, Sørensen, Patricia Diana, Hugger Jacobsen, Erik, Skov Madsen, Jonna, and Brandslund, Ivan
- Subjects
BREAST cancer research ,METASTASIS ,ANTIGENS ,HER2 protein ,DISEASE relapse ,TUMOR markers ,DIAGNOSIS - Abstract
Background: The aim of this project was to investigate the sensitivity of CA 15-3, CEA and HER2 in the early diagnosis of metastatic breast cancer. Methods: Serial serum values of CA 15-3, CEA and HER2 were determined in 107 patients with recurrence after breast cancer. Fifteen of the patients had primary disseminated disease, nine patients only developed local recurrence during the follow-up period and the remaining 83 developed distant metastases. Results: In the group of patients with distant metastatic disease (n=83), elevated serum levels of CA 15-3 (>32.4 U/mL), CEA (>2.5 µg/L for non-smokers and >10 µg/L for smokers) and HER2 (>15 µg/L) were found in 49.4%, 38.6% and 32.5%, respectively, at the time of diagnosis of recurrence. CA 15-3 was significantly better than HER2 (p=0.027). The most sensitive combination was obtained using CA 15-3/CEA (60.2%) or CA 15-3/HER2 (57.8%). Combining all three tumour markers raised the sensitivity to 63.9%. In the subgroup of patients with tissue HER2+ tumours, the sensitivity of HER2 increased to 55.6%. The best combination in this group was CEA/HER2 (66.7%). In the subgroup of patients with tissue HER2- tumours, CA 15-3 was significantly better. The best combination was CA 15-3/HER2 or CA 15-3/CEA with a sensitivity of 55.8% and 59.6%, respectively. Conclusions: The combination of several tumour markers enhances the sensitivity for detection of metastatic breast cancer. We recommend HER2 or the combination of CEA and HER2 in tissue HER2+ and CA 15-3 or the combination of CA 15-3 and CEA in tissue HER2-. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
6. Utility of testing for monoclonal bands in serum of patients with susptected osteoporosis: retrospective, cross sectional study.
- Author
-
Abrahamsen, Bo, Andersen, Ivan, Christensen, Susanne S., Skov Madsen, Jonna, and Brixen, Kim
- Subjects
OSTEOPOROSIS treatment ,CLINICAL medicine ,MEDICAL screening ,MULTIPLE myeloma ,BONE densitometry ,DISEASE risk factors - Abstract
Objective To determine whether measuring monoclonal bands (M component) in serum should be part of the investigation of patients referred to osteoporosis clinics. Design Retrospective, cross sectional, observational study. Setting Referral centre for osteoporosis in a university hospital, Denmark. Participants 799 people (685 women) aged 19 to 94 years newly referred with suspected osteoporosis. Main outcome measures Proportion of patients fulfilling the Nordic Myeloma Study Group definition for target condition and proportion of patients with other important haematological conditions. Results 4.9% (18 of 366) of patients with osteoporosis and 2.2% (9 of 408) of patients without osteoporosis had M component in serum (2 = 3.66, P = 0.04). Multiple myeloma was diagnosed in three patients with osteoporosis (absolute risk 0.8%, 95% confidence interval 0.11% to 1.7%). The relative risk of multiple myeloma in patients presenting with osteoporosis was 75 (10 to 160). As a diagnostic test for multiple myeloma in patients with osteoporosis, M component in serum had a specificity of 95.0% and a positive predictive value of 17.6%. 122 blood electrophoreses were carried out for each case of multiple myeloma diagnosed. All patients with multiple myeloma had a history of fragility fractures. If lymphoma was included as a target condition, the specificity increased to 95.3% and the positive predictive value increased to 23.5%. Monoclonal gammopathy of undetermined significance was diagnosed in 13 (3.6%) participants with osteoporosis and in eight (2.0%) participants with normal bone mineral density or osteopenia. Conclusions Patients presenting with osteoporosis should be tested for M component in serum, as 1 in 20 patients with newly diagnosed osteoporosis had multiple myeloma or monoclonal gammopathy of undetermined significance. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
7. Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study.
- Author
-
Abrahamsen B, Andersen I, Christensen SS, Skov Madsen J, and Brixen K
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers blood, Chi-Square Distribution, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Monoclonal Gammopathy of Undetermined Significance blood, Monoclonal Gammopathy of Undetermined Significance diagnosis, Multiple Myeloma blood, Multiple Myeloma diagnosis, Osteoporosis blood, Predictive Value of Tests, Retrospective Studies, Risk Factors, Sensitivity and Specificity, Myeloma Proteins analysis, Osteoporosis diagnosis
- Abstract
Objective: To determine whether measuring monoclonal bands (M component) in serum should be part of the investigation of patients referred to osteoporosis clinics., Design: Retrospective, cross sectional, observational study., Setting: Referral centre for osteoporosis in a university hospital, Denmark., Participants: 799 people (685 women) aged 19 to 94 years newly referred with suspected osteoporosis., Main Outcome Measures: Proportion of patients fulfilling the Nordic Myeloma Study Group definition for target condition and proportion of patients with other important haematological conditions., Results: 4.9% (18 of 366) of patients with osteoporosis and 2.2% (9 of 408) of patients without osteoporosis had M component in serum (chi2 = 3.66, P = 0.04). Multiple myeloma was diagnosed in three patients with osteoporosis (absolute risk 0.8%, 95% confidence interval 0.11% to 1.7%). The relative risk of multiple myeloma in patients presenting with osteoporosis was 75 (10 to 160). As a diagnostic test for multiple myeloma in patients with osteoporosis, M component in serum had a specificity of 95.0% and a positive predictive value of 17.6%. 122 blood electrophoreses were carried out for each case of multiple myeloma diagnosed. All patients with multiple myeloma had a history of fragility fractures. If lymphoma was included as a target condition, the specificity increased to 95.3% and the positive predictive value increased to 23.5%. Monoclonal gammopathy of undetermined significance was diagnosed in 13 (3.6%) participants with osteoporosis and in eight (2.0%) participants with normal bone mineral density or osteopenia., Conclusions: Patients presenting with osteoporosis should be tested for M component in serum, as 1 in 20 patients with newly diagnosed osteoporosis had multiple myeloma or monoclonal gammopathy of undetermined significance.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.